Spots Global Cancer Trial Database for oligoprogressive
Every month we try and update this database with for oligoprogressive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | NCT05846659 | Oligoprogressiv... | IMSA101 Immune checkpoi... PULSAR | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma | NCT04974671 | Renal Cell Carc... Metastatic Rena... Oligoprogressiv... Progression | Stereotactic Bo... | 18 Years - | Yale University | |
| Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer | NCT04989725 | Head and Neck C... Metastatic Canc... Oligoprogressiv... | Standard arm Experimental ar... | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors | NCT05387044 | NSCLC Stage IV | SBRT | 18 Years - | Zhejiang Cancer Hospital | |
| SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy | NCT05990192 | Ovarian Cancer ... | Niraparib oral ... SBRT | 18 Years - | Institute of Cancer Research, United Kingdom | |
| SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy | NCT05990192 | Ovarian Cancer ... | Niraparib oral ... SBRT | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer | NCT04989725 | Head and Neck C... Metastatic Canc... Oligoprogressiv... | Standard arm Experimental ar... | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) | NCT06103669 | Breast Cancer Oligoprogressiv... Head and Neck C... Sarcoma Other Cancer | Ablative local ... | 18 Years - | University of California, Davis | |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | NCT05846659 | Oligoprogressiv... | IMSA101 Immune checkpoi... PULSAR | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma | NCT04485026 | Non Small Cell ... Oligoprogressiv... | Local consolida... Standard of car... | 18 Years - | Wake Forest University Health Sciences | |
| Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) | NCT06101290 | Prostate Cancer Oligoprogressiv... Urothelial Carc... Renal Cell Carc... | Ablative local ... | 18 Years - | University of California, Davis | |
| Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer | NCT04838899 | Oligoprogressiv... Castration-Resi... | Stereotactic Bo... | 18 Years - | Sunnybrook Health Sciences Centre | |
| A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression | NCT04970693 | Non-small Cell ... Oligoprogressiv... | Furmonertinib | 18 Years - 80 Years | Sun Yat-sen University | |
| Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) | NCT06103669 | Breast Cancer Oligoprogressiv... Head and Neck C... Sarcoma Other Cancer | Ablative local ... | 18 Years - | University of California, Davis | |
| Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) | NCT06101277 | Esophageal Canc... Small Bowel Can... Gastroesophagea... Gastric Cancer Colorectal Canc... Appendiceal Can... Biliary Cancer Gall Bladder Ca... Intrahepatic Ch... Extrahepatic Ch... Oligoprogressiv... | Ablative local ... | 18 Years - | University of California, Davis | |
| SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors | NCT05387044 | NSCLC Stage IV | SBRT | 18 Years - | Zhejiang Cancer Hospital | |
| Stereotactic Magnetic Resonance Guided Radiation Therapy | NCT04115254 | Pancreas Cancer Lung Cancer Renal Cancer Adrenal Metasta... Prostate Cancer Liver Metastase... Oligoprogressiv... Metachronous No... Synchronous Nod... Mesothelioma Spine Metastase... Brain Metastase... Borderline Rese... | MR-guided Linac | 18 Years - | Dana-Farber Cancer Institute | |
| LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE) | NCT06103682 | Non-small Cell ... Oligoprogressiv... Small-cell Lung... | Ablative local ... | 18 Years - | University of California, Davis | |
| Stereotactic Magnetic Resonance Guided Radiation Therapy | NCT04115254 | Pancreas Cancer Lung Cancer Renal Cancer Adrenal Metasta... Prostate Cancer Liver Metastase... Oligoprogressiv... Metachronous No... Synchronous Nod... Mesothelioma Spine Metastase... Brain Metastase... Borderline Rese... | MR-guided Linac | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression | NCT04970693 | Non-small Cell ... Oligoprogressiv... | Furmonertinib | 18 Years - 80 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
